Insulet (PODD)
(Delayed Data from NSDQ)
$174.43 USD
+1.01 (0.58%)
Updated May 3, 2024 04:00 PM ET
After-Market: $174.45 +0.02 (0.01%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth C Momentum B VGM
Brokerage Reports
Insulet Corporation [PODD]
Reports for Purchase
Showing records 181 - 200 ( 341 total )
Company: Insulet Corporation
Industry: Medical - Products
Growth unleashed following Neighborhood Diabetes divestment, reiterate BUY
Provider: Feltl & Company
Analyst: HAYNOR B
Company: Insulet Corporation
Industry: Medical - Products
Steady Improvements with Healthy Underlying Momentum Across All Segments; Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Company: Insulet Corporation
Industry: Medical - Products
Feltl Insulin Pump Project: Historical survey of ~6,000 users
Provider: Feltl & Company
Analyst: HAYNOR B
Company: Insulet Corporation
Industry: Medical - Products
Diabetes 1Q16 Earnings Preview: Despite Seasonally Soft 1Q, Expecting Healthy Trends Driven By New Product Launches
Provider: WEDBUSH SECURITIES INC.
Company: Insulet Corporation
Industry: Medical - Products
Neulasta Onpro Kit Prescriptions Gain Significant Share in March; Maintain OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Company: Insulet Corporation
Industry: Medical - Products
Medical Devices - Takeaways from J-J''s 1Q16 Results
Provider: WEDBUSH SECURITIES INC.
Company: Insulet Corporation
Industry: Medical - Products
1Q16 MedTech Preview: Stable Trends; Prefer the Oversold Names With Solid Fundamentals
Provider: WEDBUSH SECURITIES INC.
Company: Insulet Corporation
Industry: Medical - Products
Neulasta Onpro Kit Shows a Sequential Decline in February After Very High January Sales Data, But Overall Trend Remains Positive; Maintain OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Company: Insulet Corporation
Industry: Medical - Products
"Pumped-up" sales deliver Q4 beat, guidance ahead of expectations - upgrade to BUY
Provider: Feltl & Company
Analyst: HAYNOR B
Company: Insulet Corporation
Industry: Medical - Products
Pumped about PODD''s Performance in the Quarter and Better Than Expected Guidance; Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Company: Insulet Corporation
Industry: Medical - Products
Extremely High Neulasta Onpro Kit Sales Reported in January...An Outlier or the New Reality? Maintain OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Company: Insulet Corporation
Industry: Medical - Products
Q4 2015 Insulin Pump Project: Historical survey of -6,000 users
Provider: Feltl & Company
Analyst: HAYNOR B
Company: Insulet Corporation
Industry: Medical - Products
Survey of Diabetes Educators Very Positive for DXCM''s Growth Outlook; Suggests Recent Concerns Misplaced; Reiterate OUTPERFORM on DXCM
Provider: WEDBUSH SECURITIES INC.
Company: Insulet Corporation
Industry: Medical - Products
Company: Insulet Corporation
Industry: Medical - Products
Proprietary Survey of Diabetes Educators Suggests Patients Prefer Tandem''s Insulin Pumps; Reiterate OUTPERFORM on TNDM shares
Provider: WEDBUSH SECURITIES INC.
Company: Insulet Corporation
Industry: Medical - Products
Neulasta Onpro Kit Enters 2016 with Solid Momentum and Room to Deliver Potential Upside; Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Company: Insulet Corporation
Industry: Medical - Products
Neulasta Onpro Kit Continued to Make Solid Share Gains in November; Now Represents 25% of Neulasta Franchise; Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Company: Insulet Corporation
Industry: Medical - Products
Positive (Albeit Temporary) Implications of a 2-Year Suspension of the Medical Device Tax
Provider: WEDBUSH SECURITIES INC.
Company: Insulet Corporation
Industry: Medical - Products
October Neulasta Onpro Kit Symphony Health Sales Estimate Reflects Continued Solid Share Gains; Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Company: Insulet Corporation
Industry: Medical - Products
Q3 sales beat - could OmniPod diabetes become a means to an end in drug delivery?
Provider: Feltl & Company
Analyst: HAYNOR B